Newest acquisition strengthens and broadens IMA’s clinical research offerings
With the acquisition of Diagnostics Research Group (DXRG), The IMA Group adds to its growing Clinical Research Division and furthers its capabilities to build broad research capabilities targeting a diverse range of populations. IMA’s Clinical Research Division is a physician-founded network of integrated clinical research sites specializing in Phase II-IV hybrid and fully decentralized trials in multiple therapeutic areas.
TARRYTOWN, N.Y.–(BUSINESS WIRE)–The IMA Group (IMA) announced today the acquisition of Diagnostics Research Group (DXRG), a clinical research site in San Antonio, Texas, with expertise across a diverse array of medical specialties, including vaccine and medical device development, internal medicine, allergies, and pulmonary and fatty liver diseases.
“DXRG is an exceptional addition to our Clinical Research Division. Its broad-ranging expertise in multiple indications, as well as diverse patient population base, strengthens and widens our therapeutic and geographic reach”
The acquisition marks the company’s fourth this year and extends IMA’s access to diverse patient populations and its expansion into the southwestern United States. It also adds to IMA’s growing Clinical Research Division and its more than 90 brick-and-mortar medical offices. The move aligns with IMA’s mission to reach people everywhere, as it partners with its sponsors to develop safe and effective new treatments.
“DXRG is an exceptional addition to our Clinical Research Division. Its broad-ranging expertise in multiple indications, as well as diverse patient population base, strengthens and widens our therapeutic and geographic reach,” said Mark Weinberger, PhD, MPH, President of The IMA Group.
“This acquisition takes DXRG to a new level, enabling us to provide greater access to new and improved medical treatments and devices through clinical trial participation in San Antonio and South Texas. Our extensive therapeutic expertise complements the existing capabilities of IMA Clinical Research, and our access to diverse patient populations will create synergies with existing recruitment efforts,” commented Brita Andrews, RN, MSN, CCRC, who has served as CEO of DXRG since its founding 21 years ago.
Financial terms for the two privately held companies were not disclosed. Diagnostics Research Group will continue to operate under its current name, with key leadership, investigators and staff remaining in place. Additional information regarding the capabilities of DXRG can be found at www.dxrg.com.
About IMA Clinical Research:
IMA Clinical Research, a division of The IMA Group, is a physician-founded network of integrated clinical research sites specializing in Phase II-IV clinical trials in multiple therapeutic areas. With more than 90 sites in the IMA Clinical Trial Network, IMA Clinical Research has extensive capabilities to conduct site-based, hybrid and fully decentralized clinical trials that support the development of safe and effective new treatments. The Clinical Research Division offers access to new advances in pharmacology and biotechnology for research subjects, as well as a robust database of interested clinical trial participants for pharmaceutical and device sponsors. For more information, visit www.imaresearch.com or www.theIMAgroup.com.